论文信息 - Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21 - 字舞流文

Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

H. Goldschmidt | A. Jauch | A. Benner | C. Müller-Tidow | U. Hegenbart | C. Kimmich | S. Schönland | S. Huhn | M. Basset | T. Dittrich | A. Carpinteiro | T. Hansen | K. Veelken | Tobias Terzer | Marco Basset